Recently, EvaluatePharma released the 2023 Global Pharmaceutical Top 50 ranking, of which Pfizer topped the list with $91.3 billion, and four pharmaceutical companies in China made the list. Pfizer made a lot of money on the new crown vaccine, with sales performance in 2022 drug revenue of US$91.3 billion, total revenue of US$100.33 billion, a year-on-year increase of 23%, becoming the first pharmaceutical giant with sales of more than US$100 billion. Pfizer's new crown vaccine Comirnaty's direct sales or co-sales revenue in 2022 reached US$37.806 billion, an increase of 3% year-on-year, and recorded more than US$74 billion in two years. In addition to the new crown vaccine, its newly launched new crown drug Paxlovid also sold 18.933 billion US dollars, which also made Pfizer a lot of money. AbbVie still won the second place in the top 50 this year, achieving operating income of 58.054 billion US dollars in 2022, a year-on-year increase of 3.30%; Among them, global Humira (adalimumab) net income was $21.237 billion, slightly higher than its sales of $20.694 billion in 2021. Before Humira's patent expires this year, thanks to Skyrizi's treatment of psoriasis (sales up 75.7% in 2022 to 5.2 billion Scotsmen) and the JAK inhibitor Invog (which has received seven approvals to date, including rheumatoid arthritis and more recently Crohn's disease). Johnson & Johnson's drug sales reached $50.18 billion in 2022, although revenue was not satisfactory as a number of blockbuster drug patents were about to expire. In April, the company announced a comprehensive overhaul of its infectious diseases division, including cuts to its adult RSV vaccine program, HIV and hepatitis programs. Novartis' entire pharmaceutical segment generated revenue of $50.08 billion, biting Johnson & Johnson. In 2022, Novartis' Entresto sales were nearly $5 billion, and ofadumumab grew by 200%. Merck's 2022 financial report showed growth in all business units, with global net income up 12.9% year-on-year to 22.2 billion euros ($23.6 billion).

In addition, there are four pharmaceutical companies in China on the list, namely:

• China Biopharmaceuticals (39): Total revenue in 2022 was RMB28.7 billion, 7.14% year-on-year

• Shanghai Pharmaceutical (41): Total revenue in 2022 was RMB232 billion, 7.49% year-on-year, and R&D expenses were RMB2,112 billion

• Jiangsu Hengrui Pharmaceutical (43): Total revenue in 2022 was 21.28 billion yuan, down 17.87% year-on-year, and R&D expenses were 4.887 billion

• CSPC Pharmaceutical Group (48): Total revenue in 2022 will be 30.937 billion yuan, 11.02% year-on-year, and R&D expenses will be 3.987 billion

•